Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04637: Variant p.Phe54Tyr

Cellular tumor antigen p53
Gene: TP53
Feedback?
Variant information Variant position: help 54 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Phenylalanine (F) to Tyrosine (Y) at position 54 (F54Y, p.Phe54Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are large size and aromatic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In a sporadic cancer; somatic mutation. Any additional useful information about the variant.


Sequence information Variant position: help 54 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 393 The length of the canonical sequence.
Location on the sequence: help PLPSQAMDDLMLSPDDIEQW F TEDPGPDEAPRMPEAAPPVA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         PLPS-QA--MDDLMLSPDDIEQW--FTEDPGPDEAPRMPEAAPPVA

                              SELC-PA--VDELLL-PESVVNW--LDED--SDDAPRMPAT

Rhesus macaque                PLPS-QA--VDDLMLSPDDLAQW--LTEDPGPDEAPRMSEA

Mouse                         SPHC-----MDDLLL-PQDVEEF--FEG---PSEALRVSGA

Rat                           TTATGSPNSMEDLFL-PQDVAEL--LEG---PEEALQVSAP

Pig                           SELSLAA--VNDLLLSP--VTNW--LDEN--PDDASRVPAP

Bovine                        SELS-AP--VDDLLP-YTDVATW--LDEC--PNEAPQMPEP

Rabbit                        TSLN-PP--VDDLLS-AEDVANW--LNED--PEEGLRVPAA

Sheep                         SELS-AP--VDDLLPYSEDVVTW--LDEC--PNEAPQMPEP

Cat                           SELS-SA--MNELPL-SEDVANW--LDEA--PDDASGMSAV

Chicken                       ---------MQQLPL-PEDHSNW--QELSPLEPSDPPPPPP

Xenopus laevis                ----------------LQTVTCR--LDN---LSEFPDYPLA

Zebrafish                     ---------KNLIIQPPGGGSCWDIIND---EEYLPGSFDP

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
Region 1 – 320 Interaction with CCAR2
Region 1 – 83 Interaction with HRMT1L2
Region 50 – 96 Disordered
Motif 48 – 56 TADII
Modified residue 37 – 37 Phosphoserine; by MAPKAPK5
Modified residue 46 – 46 Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG
Modified residue 55 – 55 Phosphothreonine; by TAF1 and GRK5
Alternative sequence 1 – 132 Missing. In isoform 7, isoform 8 and isoform 9.
Mutagenesis 37 – 37 S -> D. Abolishes phosphorylation by MAPKAPK5.
Mutagenesis 46 – 46 S -> A. Abolishes phosphorylation by DYRK2 and HIPK2 and acetylation of K-382 by CREBBP.
Mutagenesis 46 – 46 Missing. Alters interaction with WWOX.
Mutagenesis 55 – 55 T -> A. Blocks phosphorylation by TAF1.
Helix 47 – 55



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.